By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer ...

Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...

In an unusual development, five judges of the Islamabad High Court (IHC) have approached the chief justice of Pakistan and three high court chief justices, requesting them not to advise the ...

As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be ...

A larger bench of the Islamabad High Court (IHC) on Thursday summoned the attorney general for Pakistan (AGP) on March 6 in a case relating to the missing persons, saying that there was no ...

Early cancer detection significantly benefits survival rates. Biopsies, despite common fears, don't signify cancer and are generally painless. Different biopsy types cater to various clinical ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

The approval also highlights the importance of testing metastatic breast cancer tumours for detectable staining with a standard IHC test to identify those who may be eligible for treatment with ...